Assessment of PD-L 1 expression in a tumor improves the accuracy of predicting the risk of regional breast cancer metastases

Evgenia Zubareva, Marina Senchukova, Dmitriy Shubin, Alexander Prokofiev

Article ID: 2414
Vol 7, Issue 2, 2023

VIEWS - 61 (Abstract) 24 (PDF)


Background: Improving the accuracy of axillary lymph node (ALN) status assessment and the search for new markers associated with the risk of breast cancer (BC) metastasis continues to be an urgent problem. Aim: To establish the prognostic significance of the expression of PD-L1 in a tumor for assessing the risk of BC metastasis in ALNs. Materials and methods: A retrospective, case‒control cohort study included 158 patients aged 30 to 85 years with newly diagnosed BC. The material for the study was tumor samples obtained by trephine biopsy. The expression of PD-L1 in the tumor was studied on the invasive component of puncture biopsy specimens by immunohistochemistry using PD-L1 polyclonal antibodies. Statistical analysis was performed using Statistica 12.0 software. Receiver operating characteristic (ROC) curves for PD-L1 and Ki67 were constructed to discriminate cases with and without metastases in the ALNs. Univariate and multivariate analyses were performed to establish independent predictors associated with the risk of BC metastasis. A value of p < 0.05 was considered statistically significant. Results: According to the results, independent predictors of a high risk of BC regional metastasis were T2 (OR = 5.81, 95% CI = 1.75–19.35, p = 0.004) and T3-4 (OR = 43.07, 95% CI = 9.31–199.2, p < 0.0001) stages of BC, absence of an intraductal component (OR = 3.68, 95% CI = 1.32–10.33, p = 0.013), presence of lymphovascular invasion (OR = 3.32, 95% CI = 1.34–8.22, p = 0.009), luminal B HER2-positive (OR = 6.82, 95% CI = 1.13–42.26, p = 0.036) and triple negative (OR = 8.52, 95% CI = 1.12–64.89, p = 0.038) molecular biological subtypes of BC, and PD-L1 expression coefficient greater than 1.65 (OR = 6.39, 95% CI = 2.54–16.09, p = 0.0001). Based on the data obtained, an original noninvasive method for assessing a high risk of BC regional metastasis was developed, the sensitivity of which was 80.9%, the specificity - 82.6%, and the accuracy - 85.7%. The area under the curve (AUC) was 0.876 (95% CI = 0.818–0.924, р < 0.0001). Conclusion: The results of the study indicate that the assessment of PD-L1 expression in a tumor can improve the accuracy of predicting the risk of regional BC metastasis.


breast cancer; axillary lymph nodes; risk of BC regional metastasis; PD-L1

Full Text:



1. WHO. Breast cancer. Available online: (accessed on 30 October 2023).

2. Tanaka N, Hirano A, Hattori A, et al. Effect of adjuvant chemotherapy in patients with ER + /HER2-breast cancer, assessed by propensity score matching: Significance of nuclear grade and nodal status. Breast Cancer 2020; 28(1): 40–47. doi: 10.1007/s12282-020-01125-9

3. Hu Y, Wang S, Ding N, et al. Platelet/Lymphocyte Ratio is superior to Neutrophil/Lymphocyte Ratio as a predictor of chemotherapy response and disease-free survival in Luminal B-like (HER2-) breast cancer. Clinical Breast Cancer 2020; 20(4): e403–e409. doi: 10.1016/j.clbc.2020.01.008

4. Mok CW, Tan SM, Zheng Q, Shi L. Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer. BJS Open 2019; 3(4): 445–452. doi: 10.1002/bjs5.50157

5. Wu P, Zhao K, Liang Y, et al. Validation of breast cancer models for predicting the nonsentinel lymph node metastasis after a positive sentinel lymph node biopsy in a Chinese population. Technology in Cancer Research & Treatment 2018; 17: 1533033818785032. doi: 10.1177/1533033818785032

6. Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Molecular Cancer 2019; 18(1): 157. doi: 10.1186/s12943-019-1089-9

7. Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols modulating effects of PD-L1/PD-1 checkpoint and EMT-mediated PD-L1 overexpression in breast cancer. Nutrients 2021; 13(5): 1718. doi: 10.3390/nu13051718

8. Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Letters 2020; 468: 72–81. doi: 10.1016/j.canlet.2019.10.013

9. Sahoo S, Nayak SP, Hari K, et al. Immunosuppressive traits of the hybrid Epithelial/Mesenchymal Phenotype. Frontiers in Immunology 2021; 12: 797261. doi: 10.3389/fimmu.2021.797261

10. Brierley J, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors, 8th ed. John Wiley & Sons, Inc.; 2017.

11. Zubareva E, Senchukova M, Karmakova T. Predictive significance of HIF-1α, Snail, and PD-L1 expression in breast cancer. Clinical and Experimental Medicine 2023; 23(6): 2369–2383. doi: 10.1007/s10238-023-01026-z

12. Zhao Q, Guo Y, Liu C, Huang T. Prognostic value of PD-L1 for invasive breast cancer and its miR-34a-related mechanism of regulation. International Journal of Clinical and Experimental Medicine 2019; 12(8): 9984–9997.

13. DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA: A Cancer Journal for Clinicians 2017; 67(6): 439–448. doi: 10.3322/caac.21412

14. Luz FAC, Araújo RA, Silva MJB. Decreased survival of invasive ductal breast cancer patients with two macrometastatic lymph nodes among few resected ones: Should current sentinel-lymph-node guidelines be revised? Frontiers in Oncology 2021; 11: 669890. doi: 10.3389/fonc.2021.669890

15. Yu Y, Wang Z, Wei Z, et al. Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1–2 positive sentinel lymph node macro-metastases: A retrospective analysis of two independent cohorts. BMC Cancer 2021; 21(1): 466. doi: 10.1186/s12885-021-08178-9

16. Bishop JA, Sun J, Ajkay N, Sanders MAG. Decline in frozen section diagnosis for axillary sentinel lymph nodes as a result of the american college of surgeons oncology group Z0011 trial. Archives of Pathology & Laboratory Medicine 2015; 140(8): 830–835. doi: 10.5858/arpa.2015-0296-oa

17. Lerttiendamrong B, Treeratanapun N, Vacharathit V, et al. Is routine intraoperative frozen section analysis of sentinel lymph nodes necessary in every early-stage breast cancer? Breast Cancer 2022; 14: 281–290. doi: 10.2147/bctt.s380579

18. Shojaee L, Abedinnegad S, Nafisi N, et al. Sentinel node biopsy in early breast cancer patients with palpable axillary node. Asian Pacific Journal of Cancer Prevention: APJCP 2020; 21(6): 1631–1636. doi: 10.31557/apjcp.2020.21.6.1631

19. Laohawiriyakamol S, Mahattanobon S, Puttawibul P. Intraoperative molecular analysis of total tumor load in sentinel lymph node: A predictor of axillary status in early breast cancer. Asian Pacific Journal of Cancer Prevention: APJCP 2022; 23(1): 349–354. doi: 10.31557/apjcp.2022.23.1.349

20. Lale A, Yur M, Özgül H, et al. Predictors of non-sentinel lymph node metastasis in clinical early stage (cT1-2N0) breast cancer patients with 1-2 metastatic sentinel lymph nodes. Asian Journal of Surgery 2020; 43(4): 538–549. doi: 10.1016/j.asjsur.2019.07.019

21. Xiang K, Chen J, Min Y, et al. A multi-dimensional nomogram to predict non-sentinel lymph node metastases in T1–2HR+ breast cancer. Frontiers in Endocrinology 2023; 14: 1121394. doi: 10.3389/fendo.2023.1121394

22. Guo X, Liu Z, Sun C, et al. Deep learning radiomics of ultrasonography: Identifying the risk of axillary non-sentinel lymph node involvement in primary breast cancer. EBioMedicine 2020; 60: 103018. doi: 10.1016/j.ebiom.2020.103018

23. Niu Z, Xiao M, Ma L, et al. The value of contrast-enhanced ultrasound enhancement patterns for the diagnosis of sentinel lymph node status in breast cancer: Systematic review and meta-analysis. Quantitative Imaging in Medicine and Surgery 2022; 12(2): 936–948. doi: 10.21037/qims-21-416

24. Ceylan C, Pehlevan Ozel H, Agackiran I, et al. Preoperative predictive factors affecting sentinel lymph node positivity in breast cancer and comparison of their effectiveness with existing nomograms. Medicine 2022; 101(48): e32170. doi: 10.1097/md.0000000000032170

25. Yu Y, Tan Y, Xie C, et al. Development and validation of a preoperative magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with early-stage breast cancer. JAMA Netw Open 2020; 3(12): e2028086. doi: 10.1001/jamanetworkopen.2020.28086

26. Bae SJ, Youk JH, Yoon CI, et al. A nomogram constructed using intraoperative ex vivo shear-wave elastography precisely predicts metastasis of sentinel lymph nodes in breast cancer. European Radiology 2019; 30(2): 789–797. doi: 10.1007/s00330-019-06473-5

27. Alsuliman A, Colak D, Al-Harazi O, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Molecular Cancer 2015; 14(1): 149. doi: 10.1186/s12943-015-0421-2

28. Li F, Ren Y, Wang Z. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients’ clinical parameters. Journal of Cancer Research and Therapeutics 2018; 14(1): 150–154. doi: 10.4103/jcrt.JCRT_602_17

29. Cirqueira MB, Mendonça CR, Noll M, et al. Prognostic role of PD-L1 expression in invasive breast cancer: A systematic review and meta-analysis. Cancers 2021; 13(23): 6090. doi: 10.3390/cancers13236090

30. Zhou T, Xu D, Tang B, et al. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis. Anti-Cancer Drugs 2018; 29(9): 904–910. doi: 10.1097/cad.0000000000000683

31. Catacchio I, Silvestris N, Scarpi E, et al. Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Translational Oncology 2019; 12(3): 585–595. doi: 10.1016/j.tranon.2018.12.005

32. Evangelou Z, Papoudou-Bai A, Karpathiou G, et al. PD-L1 expression and tumor-infiltrating lymphocytes in breast cancer: Clinicopathological analysis in women younger than 40 years old. In Vivo 2020; 34(2): 639–647. doi: 10.21873/invivo.11818

33. Stovgaard ES, Dyhl-Polk A, Roslind A, et al. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: A systematic review. Breast Cancer Research and Treatment 2019; 174(3): 571–584. doi: 10.1007/s10549-019-05130-1

34. Derouane F, van Marcke C, Berlière M, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: Current and future perspectives for precision medicine. Cancers 2022; 14(16): 3876. doi: 10.3390/cancers14163876

35. Zheng J, Cai S, Song H, et al. Positive non-sentinel axillary lymph nodes in breast cancer with 1-2 sentinel lymph node metastases. Medicine 2018; 97(44): e13015. doi: 10.1097/md.0000000000013015

36. Alsumai TS, Alhazzaa N, Alshamrani A, et al. Factors predicting positive sentinel lymph node biopsy in clinically node-negative breast cancer. Breast Cancer 2022; 14: 323–334. doi: 10.2147/bctt.s373005

37. Available online: location (accessed on 25 October 2023).

38. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy—Blockade, knockdown, or inhibition. Frontiers in Immunology 2019; 10: 2022. doi: 10.3389/fimmu.2019.02022

39. Parra ER, Villalobos P, Rodriguez-Canales J. The multiple faces of programmed cell death ligand 1 expression in malignant and nonmalignant cells. Applied Immunohistochemistry & Molecular Morphology 2019; 27(4): 287–294. doi: 10.1097/pai.0000000000000602

40. Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nature Reviews. Cancer 2022; 22(3): 174–189. doi: 10.1038/s41568-021-00431-4

41. Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 2016; 7(22): 32318–32328. doi: 10.18632/oncotarget.8698

42. Reimer T. Omission of axillary sentinel lymph node biopsy in early invasive breast cancer. The Breast 2023; 67: 124–128. doi: 10.1016/j.breast.2023.01.002



  • There are currently no refbacks.

Copyright (c) 2023 Evgenia Zubareva, Marina Senchukova, Dmitriy Shubin, Alexander Prokofiev

License URL:

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.